SONOMOTION COMPLETES ENROLLMENT IN PIVOTAL CLINICAL TRIAL FOR BREAK WAVE™ SYSTEM AND SECURES $2.2 MILLION NIH GRANT
Summary
The SOUND trial is a 64-patient, prospective, multi-center, non-randomized study designed to evaluate the safety and effectiveness of the Break Wave system for fragmentation of stones in the kidney or ureter. Kidney stones affect one in 10 people in the U.S., costing $10 billion annually1 and resulting in +750,000 annual procedures typically requiring anesthesia and a surgical suite. This is a testament to our mission to fundamentally change how kidney stones are treated," commented Oren Levy, PhD, Co-Founder and CEO, SonoMotion. "SonoMotions platform has the potential to be a first-line treatment for kidney stones, offering a solution for patients who want to avoid anesthesia, without the wait time or cost associated with a surgical suite. "The SonoMotion solution will be featured at booth #1807 during the upcoming 2025 American Urological Association (AUA) meeting, April 26-29 in Las Vegas.ABOUT SONOMOTIONSonoMotion, a venture capital backed startup based in San Mateo, CA, is a clinical stage medical technology company developing next-generation, noninvasive solutions for the treatment of kidney stones.